PubMed Health⌕ Search

Biomedical subjects

P Fourneret

Publications and source records attributed to P Fourneret.

At least 19 recordsLinked to original sources
PubMed2006

[Retrospective analysis of 108 ductal carcinomas in situ of the breast treated by radiosurgery association].

PURPOSE: To evaluate survival and prognostic factors of 108 patients with clinically or mammographically detected ductal carcinoma in situ (DCIS), treated from 1980 to 1996 by complete local excision followed by external irradiation. PATIENTS AND METHODS: The median age was 51 (range 37-80). All the patients underwent surgery consisting of a wide resection of the mammary gland harbouring the tumour. The surgical specimens were sent to the pathologists to get information on histology and margin clearance; all the slides were reviewed by one of us to assess the tumoral diameter. External beam therapy was delivered within 8 weeks after surgery. The prescribed irradiation dose was 50 Gy in 25 fractions to be given in 5 weeks. The median duration of follow-up was 93 months (range 40-173). RESULTS: There were nine patients with local recurrence (8.3%); three patients had local recurrence of DCIS and six patients developed invasive breast cancer. The treatment of local recurrence consisted of mastectomy with or without axillary dissection (eight cases) and quadrantectomy (one case). The 5-year and 10-year ipsilateral recurrence-free rate was respectively 92 and 89%. The 10-year cause specific survival was 100%. In univariate analysis, size>or=10 mm, age<45 years old and margin status were significant P=0,02, P=0,03, P=0,005; margin status was significant in multivariate analysis (P<0,02). CONCLUSION: These results are in keeping with those of the literature. They could be improved by the mass screening campaign, which is going on since January 1990 among women aged 50-74 years.

Aged↗
PubMed2006

[Quantification of prostate movements during radiotherapy].

Decrease treatment uncertainties is one of the most important challenge in radiation oncology. Numerous techniques are available to quantify prostate motion and visualise prostate location day after day before each irradiation: CT-scan, cone-beam-CT-Scan, ultrason, prostatic markers... The knowledge of prostate motion is necessary to define the minimal margin around the target volume needed to avoid mispositioning during treatment session. Different kind of prostate movement have been studied and are reported in the present work: namely, those having a large amplitude extending through out the whole treatment period on one hand; and those with a shorter amplitude happening during treatment session one the other hand. The long lasting movement are mostly anterior-posterior (3 mm standard deviation), secondary in cranial-caudal (1-2 mm standard deviation) and lateral directions (0.5-1 mm standard deviation). They are mostly due to the rectal state of filling and mildly due to bladder filling or inferior limbs position. On the other hand, the shorter movement that occurs during the treatment session is mostly variation of position around a steady point represented by the apex. Ones again, the rectal filling state is the principle cause. This way, during the 20 minutes of a treatment session, including the positioning of the patient, a movement of less than 3 mm could be expected when the rectum is empty. Ideally, real time imaging tools should allow an accurate localisation of the prostate and the adaptation of the dosimetry before each treatment session in a time envelope not exceeding 20 minutes.

Environmental Monitoring↗
PubMed2005

[Attention deficit and hyperactivity disorder or multiplex developmental disorders in child? Let us be sure...].

Personality disorders in child can be easily confused -- initially at least -- with Attention Deficit and Hyperactivity Disorder (ADHD). Because of the therapeutic and prognostic stake related to the early psychiatric care of Child Developmental Personality Disorders it is important to sensitize pédiatric and general practitioner with the clinical screening of these disorders. Indeed any premature prescription of psychostimulant treatment in these children can have regrettable consequences on their psychic functioning already precarious.

Attention Deficit Disorder with Hyperactivity↗
PubMed2005

Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer.

Patients with nonsmall cell lung cancer (NSCLC) have been shown to have a higher prevalence of comorbidity associated with age and tobacco consumption. The objective of the present study was to determine the impact of comorbidity on survival after surgery of stage I NSCLC. In total, 588 consecutive patients operated on for a pathological stage I NSCLC between January 1, 1979 and December 31, 2003 were studied. Comorbidities were analysed individually. Overall comorbidity was assessed using the Charlson index of comorbidity (CCI). Survival data were collected for each patient from the date of operation, with a median duration of follow-up of 104 months. Survival analyses and Cox proportional hazards model analyses were used. The mean age of patients was 62.7 yrs, and 529 (89%) patients were male. The distribution of overall comorbidity severity was as follows. CCI grade 0: 47.1%; grade 1-2: 43.7%; grade 3-4: 8.3%; and grade > or =5: 0.8%. The 2, 3 and 5 yrs survival were 69, 62 and 50%, respectively. Multivariable analysis showed that T stage, age, a concomitant history of moderate-to-severe liver disease, a past history of cured cancer, cerebrovascular disease and CCI were independent predictors of survival (Hazard Ratio for CCI grade >2: 1.81; 95% confidence interval 1.25-2.63). In conclusion, comorbidity has a significant impact on survival after surgical resection of patients with stage I nonsmall cell lung cancer. The use of a validated index of comorbidity in prognostic analyses of resected nonsmall cell lung cancer is recommended.

Adult↗
PubMed2004

[Psychophysiological factors in high intellectual potential: comparative study in children aged from 8 to 11 years old].

UNLABELLED: Factors of intellectual talent as well as physiological and psychological characteristics are little known. However, giftedness is now a social problem and the knowledge of precocity hallmarks should permit the diagnosis in order to undertake the adequate educational orientation of these children. From questionnaires given anonymously to parents, this work showed comparative results between a population of gifted children and a control one. OBJECTIVES: The aim of this study was to present precocity hallmarks in the gifted population, following factorial analysis of socio-economic and familial parameters, as well as medical and psycho-physiological variables linked with the children's post-natal life. POPULATION: Four hundred and twelve children aged eight to 11 years, from Lyon, have been used in the survey: 217 children (control group) were included after a random selection in schools, and 195 children (gifted group, IQ >130, Wechsler test) were enrolled after clinician's diagnoses in four medical departments. RESULTS: Regression analysis allowed to draw relation between several factors and giftedness: abnormal pregnancy (CR =3.205, P =0.009), perinatal stress (CR =2.166, P =0.003), and presence of migraine (CR =3.169, P =0.001). Parents living together (married or not) (CR =2.100, P =0.080) with a good and superior level of learning (CR =5.464, P =0.0002) were also linked with giftedness. CONCLUSION: Our results indicate that precocity hallmarks are multifactorial. These data confirm some socio-economic and medical physiological features correlated with giftedness, and suggest that psychological factors may bear on the etiology of intellectual talent. We focus on the hypothesis than early stress may play a role on central nervous system maturation in these children.

Child↗
PubMed2004

[Diagnosis and therapeutic current approach of obsessive compulsive disorder in children].

In the past years, obsessive-compulsive disorder has mainly been described in adults. However, recent epidemiological data has shown that 2 to 3% of the school-age population has OCD symptoms in the clinical range of severity. Despite these findings, this disorder remains still unknown and under recognized by child's clinicians--general practitioners, paediatricians or child and adolescent psychiatrists. This may contribute to the particularly damaging delay occurring in diagnosis and specific treatment of childhood onset OCD. Therefore, this article intends to review the main clinical signs likely to allow an early detection of OCD in child as well as the principal therapeutic methods currently in progress.

Child↗
PubMed2004

The sense of agency: a philosophical and empirical review of the "Who" system.

How do I know that I am the person who is moving? According to Wittgenstein (1958), the sense of agency involves a primitive notion of the self used as subject, which does not rely on any prior perceptual identification and which is immune to error through misidentification. However, the neuroscience of action and the neuropsychology of schizophrenia show the existence of specific cognitive processes underlying the sense of agency--the "Who" system--which is disrupted in delusions of control. Yet, we have to be careful in the interpretation of such clinical symptoms, which cannot be so easily reduced to deficit of action monitoring or to lack of action awareness. Moreover, we should refine the definition of the sense of agency by distinguishing the sense of initiation and the sense of one's own movements. A conceptual analysis of the empirical data will lead us to establish the taxonomy of the different levels of action representations.

Cognition↗
PubMed2003

The prefrontal cortex and conscious monitoring of action: an experimental study.

To investigate the role of the prefrontal cortex in conscious monitoring, we used an experimental paradigm generating a conflict between the action planned and the sensory-motor feedback. We analyzed the acquisition of explicit knowledge of the strategy for resolving the conflict and its influence on motor adaptation. Twenty patients with frontal lobe lesions and 18 controls had to trace a sagittal line with a stylus on a graphics tablet. A mirror on which the traced line, processed by a computer, was projected hid the hand. A mask limited visual feedback to the last third of the trajectory. Without informing the subjects, the line traced was modified by introducing a bias of 24 degrees to the right. To succeed in the task, subjects had to modify their motor program and to deviate their trajectory in the opposite direction. Conscious elaboration of the strategy was evaluated by the number of trials needed to explicitly report the required deviation. Three groups of patients were distinguished: (1). with normal explicit strategy; (2). with delayed explicit strategy, and (3). without explicit strategy at the last trial. They significantly differed by the severity of the dysexecutive syndrome, particularly of environmental adherence. Motor adaptation was evaluated by the area between the line traced and the ideal line to compensate for the deviation. In patients with normal elaboration of the strategy, motor control was similar to that of controls, but it was severely disturbed in the other two groups. These results suggest the involvement of the prefrontal cortex in conscious motor monitoring.

Adaptation, Physiological↗
PubMed2001

Attention shifts and anticipatory mechanisms in hyperactive children: an ERP study using the Posner paradigm.

BACKGROUND: The aim of this study was to assess attentional, decisional, and motor processing stages during the performance of an attention shifting paradigm, both in normal children and children with attention-deficit/hyperactivity disorder (ADHD). METHODS: We recorded event-related potentials (ERPs) and performance measures during a variant of the Posner paradigm in 13 control subjects and 24 ADHD children. Subjects responded with a spatially concordant motor response to left or right visual targets, which could be either preceded by a spatial cue ("valid" = same side; "invalid" = opposite side) or presented uncued. RESULTS: Patients made significantly more errors than control subjects, with predominance of the anticipatory type. As compared to control subjects, ADHD children had faster reaction times, as well as a shortened interval between the N2 and P3 ERPs and the motor response. Patients also showed a decreased attentional priming effect on early sensory responses (P1). Finally, the slow negativity (contingent negative variation/readiness potential) that preceded the target in the "no cue" condition was absent in ADHD patients. CONCLUSIONS: The combined analysis of electrophysiological and behavioral data suggest a characteristic mode of response of ADHD in attention shifting tasks, characterized by "motor impulsivity" with release of motor responses before stimulus processing is adequately completed, as well as a lack of strategic planning/anticipatory mechanisms in the absence of warning stimulus. These deficits may be partly attributed to dysmaturation of executive frontal functions. In addition, a minor deficit in early attentional priming was also observed in ERPs, with no apparent behavioral counterparts.

Attention Deficit Disorder with Hyperactivity↗
PubMed2001

Self-monitoring in schizophrenia revisited.

According to a widespread theory, the first-rank symptoms such as delusions of control or thought insertion met in schizophrenia result from a failure in predicting the consequences of an action on the basis of a forward model based of the intended motor commands (efference copy). This assumption of an impairment in the central monitoring of their own actions is inferred from experiments showing that it is more difficult for schizophrenic patients than for controls to correct erroneous movements in the absence of visual feedback. In our study, 19 schizophrenic patients (10 with Schneiderian symptoms and nine without) and 19 paired control subjects were subjected to a sensorimotor adjustment task to reassess this hypothesis. We show that the patients who succeeded the task not differently from the control subjects were those who were aware of the manual correction (n = 9). Surprisingly, most of them presented Schneiderian symptoms. This suggests that the experience of alien control observed in certain schizophrenic patients cannot be directly related to an underlying cognitive deficit in the conscious monitoring of their own actions.

Adult↗
PubMed2001

Preserved adjustment but impaired awareness in a sensory-motor conflict following prefrontal lesions.

Control of action occurs at different stages of the executive process, in particular at those of sensory-motor integration and conscious monitoring. The aim of this study was to determine the implication of the prefrontal cortex in the control of action. For that purpose, we compared the performance of 15 patients with frontal lobe lesions and 15 matched controls on an experimental paradigm generating a conflict between the action planned and the sensory-motor feedback. Subjects had to trace a sagittal line with a stylus on a graphic tablet. The hand was hidden by a mirror on which the traced line, processed by a computer, was projected. Without informing the subjects, the line traced was modified by introducing a bias to the right, which increased progressively from 2 degrees to 42 degrees. To succeed the task, subjects had to modify their motor program and deviate their hand in the opposite direction. The sensory-motor adjustment to the bias was evaluated by the surface between the line traced and the ideal line to compensate for the deviation. The awareness of the conflict was measured by the angle of the bias at which subjects expressed the feeling that the line they traced was not the same as the line they saw. The deviation was similarly compensated for by patients and controls until 24 degrees. Then 14 controls but only 3 patients were aware of a conflict. After that, the variability of performance increased significantly for the unaware patients. These results suggest that the prefrontal cortex is required at the level of conscious monitoring of actions, but not at the level of sensory-motor integration.

Adult↗
PubMed2001

[Cognitive-behavioral management of sleep disorders in young children].

Sleep disorders are prevalent in young children, the most frequent being disturbances in initiating and maintaining sleep. Behavioral and cognitive approaches are interesting techniques for their management. They can be used either for solving sleep problems at home, or in severe forms as part of a 'deconditioning' during a short hospitalization.

Behavior Therapy↗
PubMed2000

[Decisional procedure in school-age children with hyperkinetic syndrome].

Hyperkinetic syndrome may be either secondary to an organic disease or a psycho-effective disorder (mood and/or anxiety disorder), or primary as part of an attention deficit hyperactivity disorder. Precise diagnosis is essential before any therapeutic decision; this requires a complete anamnestic, behavioural, psychological, sensorial, and neurological evaluation. It is only when a reliable diagnosis has been made that a relevant therapeutic project can be proposed. An evaluation procedure and a decisional tree are presented.

Adolescent↗
PubMed1999

[School refusal anxiety].

School refusal mainly affects 11-13-year-old children but may be observed at any age from 5 to 15 years. It has two main clinical varieties: 1) school phobia in which the refusal attitude is directed toward school itself or an aspect of school environment; 2) separation anxiety in which the refusal of going to school is related to the separation with attached relatives, frequently the mother. Early recognition and intervention are determining factors for the prognosis. Hospital management and/or medication (imipramine) may be necessary in severe forms.

Adolescent↗
PubMed1998

Limited conscious monitoring of motor performance in normal subjects.

Normal subjects traced sagittal lines on a graphic tablet using a stylus held in their right hand. The hand was hidden by a mirror in which they saw the lines projected from a computer screen. In normal trials, the line seen in the mirror exactly corresponded to the traced line. In perturbed trials, a bias was introduced by the computer, so that the line appeared to deviate in one direction (right or left) by a variable angle (2, 5, 7 or 10 degrees). Subjects consistently displaced their hand in the opposite direction for producing a visually sagittal line. After each trial, they were asked in which direction they thought their hand had moved. In perturbed trials, they grossly underestimated the hand deviation. In addition, a post-hoc analysis revealed that one group of subjects misperceived the direction of their hand movement in the direction opposite to the perturbation (Group 1, including 9 Ss), whereas the other group gave responses in the correct direction (Group 2, including 4 Ss). In a second session using the same experimental paradigm, a motor response was asked for: subjects had to indicate the perceived direction of their hand during each trial by drawing a line with their eyes closed. Again, responses indicated a poor conscious monitoring of motor performance. These results suggest that normal subjects are not aware of signals generated by their own movements.

Adult↗
PubMedDate not supplied

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

This paper provides a review of safety and efficacy data as well as of pharmacological characteristics of atomoxetine, a new drug treatment for the Attention Deficit/Hyperactivity Disorder (ADHD). To date, the only pharmacological treatment available in France for children and adolescents diagnosed with ADHD is methylphenidate, a psychostimulant drug. However, the clinical response to methylphenidate may be absent or insufficient in about 20-30% drug-treated children while the occurrence of adverse effects with methylphenidate (sleep disturbances, loss of appetite, tics increase...) may sometimes require a dose reduction or even the discontinuation of the treatment. Atomoxetine is an alternative candidate drug for the treatment of ADHD. The drug has been developed with respect to the actual standards of investigation of drugs intended to a -pediatric use. Atomoxetine has been recently licensed in the USA for the treatment of ADHD. Atomoxetine is a potent inhibitor of the norepinephrine transporter that shows only mini-mal affinity for other neurotransmitter systems. Although pharmacokinetics of atomoxetine is influenced by the polymorphism of the CYP2D6 metabolic pathway, safety and -tolerability data reported during clinical trials did not show any difference in poor versus extensive metabolizers. In addition, atomoxetine does not inhibit nor induce the CYP2D6 enzymatic function. The major metabolite of atomoxetine is 4-hydroxyatomoxetine, a pharmacologically active metabolic found in very low plasma concentrations in pediatric patients, suggesting that it plays only a minor role in the norepinephrine reuptake inhibition. Preliminary studies were aimed to assess the effective dose range of atomoxetine and to evaluate its safety and efficacy on the reduction of ADHD symptoms in adults and children diagnosed with ADHD. Main data on the child and adolescent population were obtained in four double-blind, randomized, placebo-controlled trials: two identical pivotal trials, a multiple dose study, a once-daily dose study. The first two pivotal trials were carried out in ADHD children aged 7-13 years, treated with atomoxetine vs placebo for a duration of 9 weeks. Patients presenting comorbidities (ie conduct disorder, -anxiety, depression) as well as a history of previous treatment with methylphenidate were also eligible to participate. The primary outcome was the reduction of the score on the ADHD rating scale, ADHD-RS ; secondary criteria included the responder's rate (patients with an ADHD-RS score reduction of 25% or above), the Clinical Global Impression Scale and the Conners Parent Rating Scale. With a mean dose of 1.5 mg/kg/day, atomoxetine showed a significant reduction of mean ADHD-RS scores at endpoint (ANOVA, p<0.001) (table II). Yet, the clinical significance of both studies is limited since efficacy was scored only in a social/familial setting and not in classroom conditions. In addition, intermediate results from baseline to endpoint were not presented in the publication. The multiple dose trial showed a significant reduction of the symptom score at the 1.2 and 1.8 mg/kg/day doses. The objective of the last study was to assess the efficacy of a single daily dose of atomoxetine versus placebo during a 6 week-treatment. Patients were evaluated by parents, investigators, as well as by teachers. The superiority of atomoxetine was demonstrated as compared to the placebo and the effect size of the daily dosing was similar to that reported with multiple doses. Preliminary data on ADHD patients presenting comorbidities showed that atomoxetine alone signi-ficantly reduced the symptom scores of anxiety and depression and similarly to atomoxetine associated with fluoxetine. In ADHD children with the oppositional defiant disorder, oppositional symptoms were reduced in the group receiving atomoxetine 1.8 mg/kg/day. Preliminary results in children with ADHD and chronic tics or Tourette syndrome showed a significant reduction of ADHD symptoms and a tendency to the decrease of tics. Tolerance and safety data pooled from the child and adolescent trials were acceptable. Study discontinuations due to adverse events in the four registration studies were only 2.8%. The most frequent adverse effects reported were gastrointestinal symptoms and decreased appetite. Weight loss reported early in clinical studies tended to stabilize during the open-label extension phases lasting up to 9 months. A retrospective comparison showed that the adverse event profile of poor metabolizers was similar to that of extensive metabolizers. In summary, data presented suggest that atomoxetine is a safe and effective drug for the treatment of ADHD in children and adolescents. Further studies are expected to accurately define the place of atomoxetine in the treatment strategy of ADHD, a chronic and invalidating disorder affecting 3 to 7% of school-aged children.

Adolescent↗